LHA510 Proof-of-Concept Study as a Maintenance Therapy for Patients With Wet Age-Related Macular Degeneration

On Day -1, patients will receive an IVT Lucentis® injection in the study eye, and then will
be randomized to receive either topical LHA510 ophthalmic suspension or vehicle in a 1:1
ratio for 84 days. Patients with recurrence of active CNV in the study eye during the study
will receive rescue IVT Lucentis® injections. Following the treatment period, subjects will
return for a follow-up visit and a disposition visit. Only one eye (designated as the study
eye) will be dosed with either topical LHA510 or vehicle per patient.

Inclusion Criteria:

- Sign written informed consent form;

- Wet AMD;

- IVT anti-VEGF therapy for at least 6 months and a maximum of 7 years since the 3rd
loading dose;

- BCVA 50 letters (approximate Snellen equivalent 20/100) or better in the study eye;

- Demonstrate ability to administer eye drops (subject or care-giver);

- CNV recently demonstrated high need for frequent anti-VEGF therapy and a sustained
functional and clear anatomical response to the therapy in the study eye;

- Other protocol-specified inclusion criteria may apply.

Exclusion Criteria:

- Any active ocular or periocular infection or intraocular inflammation;

- Current or history of macular or retinal disease (if visually significant) other than
wet AMD in the study eye;

- Current clinically significant vitreous hemorrhage or history of rhegmatogenous
retinal detachment affecting the macula in the study eye;

- History of hypersensitivity to any of the study drugs or clinically relevant
sensitivity to fluorescein dye or povidone iodine;

- Women of child-bearing potential;

- History of a medical condition that, in the opinion of the Investigator, would
preclude scheduled study visits, completion of the study or a safe administration of
investigational product;

- Other protocol-specified exclusion criteria may apply.